BCYC News and Press, Bicycle Therapeutics plc From 07/18/23

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced the closing on Monday, July 17, 2023 of its underwritten public offering of 6,117,...

2023-07-13 18:40:28 ET Investors were more than willing to take a ride with Bicycle Therapeutics (NASDAQ: BCYC) on Thursday. The U.K.-based biotech saw the price of its American Depositary Shares (ADSes) surge more than 19% higher on the day; news about a new round of capital raisin...

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the pricing of an underwritten public offering of 9,411,766 American Deposita...

2023-07-12 16:10:15 ET Bicycle Therapeutics ( NASDAQ: BCYC ) plans to conduct a public offering of its American Depositary Shares to raise $200 million, the company said Wednesday. Each ADS represents one ordinary share and, in lieu of ADSs for investors that so choose, ...

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that it has commenced an underwritten public offering of $200 million of Amer...

2023-06-23 07:48:18 ET Bicycle Therapeutics ( NASDAQ: BCYC ) notifies the appointment of Alethia Young as its new Chief Financial Officer, effective July 17, to succeed Lee Kalowski, who served as Bicycle’s CFO since 2017. Most recently, Young se...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Alethia Young as its new Chief Financial Officer, eff...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the TD Cowen Radiopha...

2023-05-14 07:16:59 ET Summary BCYC's distinction is that it is founded by a Nobel laureate. However, unless it can differentiate its product's efficacy from that of mAbs, that may be its only distinction. So far, it has not been strikingly successful. I covered Bicy...

Bicycle Therapeutics Plc (NASDAQ: BCYC) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 4.17% on the day to $23.97. Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicine...